New clues for nephrotoxicity induced by ifosfamide: Preferential renal uptake via the human organic cation transporter 2

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 270-279

  Ciarimboli, Giuliano ^a   Holle, Svenja Kristina ^a   Vollenbröcker, Beate ^a   Hagos, Yohannes ^b   Reuter, Stefan ^a   Burckhardt, Gerhard ^b   Bierer, Stefan ^a   Herrmann, Edwin ^a   Pavenstädt, Hermann ^a   Rossi, Rainer ^c   Kleta, Robert ^d   Schlatter, Eberhard ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Fanconi syndrome; Human kidney; Isolated proximal tubule; Nephrotoxicity; Oxazaphosphorine

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; IFOSFAMIDE; ORGANIC CATION TRANSPORTER 2;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MALE; MEMBRANE POTENTIAL; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CELLS, CULTURED; CIMETIDINE; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1;

EID: 79952124892     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100329u     Document Type: Article

References (41)

1. Dechant, K. L.; Brogden, R. N.; Pilkington, T.; Faulds, D. Ifosfamide/Mesna. A Review of Its Antineoplastic Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cancer. Drugs 1991, 42, 428-467. (Pubitemid 21920771)
2. Huang, Z.; Roy, P.; Waxman, D. J. Role of Human Liver Microsomal CYP3A4 and CYP2B6 in Catalyzing N-Dechloroethylation of Cyclophosphamide and Ifosfamide. Biochem. Pharmacol. 2000, 59, 961-972. (Pubitemid 30110812)
3. Kleta, R. Cyclophosphamide and Mercaptoethane Sulfonate Therapy for Minimal Lesion Glomerulonephritis. Kidney Int. 1999,56, 2312-2313. (Pubitemid 30004768)
4. Rossi, R.; Pleyer, J.; Schafers, P.; Kuhn, N.; Kleta, R.; Deufel,T.; Jurgens, H. Development of Ifosfamide-Induced Nephrotoxicity: Prospective Follow-Up in 75 Patients. Med. Pediatr. Oncol.1999, 32, 177-182. (Pubitemid 29095976)
5. Skinner, R.; Pearson, A. D.; Price, L.; Coulthard, M. G.; Craft,A. W. Nephrotoxicity After Ifosfamide. Arch. Dis. Child 1990,65, 732-738. (Pubitemid 20220431)
6. Dubourg, L.; Michoudet, C.; Cochat, P.; Baverel, G. Human Kidney Tubules Detoxify Chloroacetaldehyde, a Presumed Nephrotoxic Metabolite of Ifosfamide. J. Am. Soc. Nephrol. 2001, 12,1615-1623. (Pubitemid 32674423)
7. Mohrmann, M.; Ansorge, S.; Schmich, U.; Schonfeld, B.; Brandis,M. Toxicity of Ifosfamide, Cyclophosphamide and Their Metabolitesin Renal Tubular Cells in Culture. Pediatr. Nephrol. 1994,8, 157-163. (Pubitemid 24092249)
8. Zamlauski-Tucker, M. J.; Morris, M. E.; Springate, J. E. Ifosfamide Metabolite Chloroacetaldehyde Causes Fanconi Syndrome in the Perfused Rat Kidney. Toxicol. Appl. Pharmacol. 1994, 129, 170-175. (Pubitemid 24352635)
9. Rossi, R. Nephrotoxicity of Ifosfamide-Moving Towards Understanding the Molecular Mechanisms. Nephrol., Dial., Transplant.1997, 12, 1091-1092. (Pubitemid 27230536)
10. Rossi, R.; Kleta, R.; Ehrich, J. H. Renal Involvement in Children With Malignancies. Pediatr. Nephrol. 1999, 13, 153-162. (Pubitemid 29206244)
11. Zhang, J.; Tian, Q.; Yung, C. S.; Chuen, L. S.; Zhou, S.; Duan,W.; Zhu, Y. Z. Metabolism and Transport of Oxazaphosphorines and the Clinical Implications. Drug Metab Rev. 2005, 37, 611-703. (Pubitemid 43071142)
12. Stachon, A.; Hohage, H.; Feidt, C.; Kleta, R.; Schlatter, E.Cytostatics and Neurotransmitters Are Transported by the Organic Cation Transporter in Proximal Cells. Nova Acta Leopold. 1998,78, 333-338.
13. Ullrich, K. J.; Rumrich, G.; David, C.; Fritzsch, G. Bisubstrates: Substances That Interact With Both, Renal Contraluminal Organic Anion and Organic Cation Transport Systems. II. Zwitterionic Substrates: Dipeptides, Cephalosporins, Quinolone-Carboxylate Gyrase Inhibitors and Phosphamide Thiazine Carboxylates; Nonionizable Substrates: Steroid Hormones and Cyclophosphamides. Pfluegers Arch. 1993, 425, 300-312. (Pubitemid 23338848)
14. Rizwan, A. N.; Burckhardt, G. Organic Anion Transporters ofthe SLC22 Family: Biopharmaceutical, Physiological, and PathologicalRoles. Pharm. Res. 2007, 24, 450-470. (Pubitemid 46295167)
15. Gorboulev, V.; Ulzheimer, J. C.; Akhoundova, A.; Ulzheimer-Teuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.;Busch, A. E.; Koepsell, H. Cloning and Characterization of Two Human Polyspecific Organic Cation Transporters. DNA Cell Biol.1997, 16, 871-881. (Pubitemid 27332696)
16. Aleksa, K.; Matsell, D.; Krausz, K.; Gelboin, H.; Ito, S.; Koren,G. Cytochrome P450 3A and 2B6 in the Developing Kidney: Implications for Ifosfamide Nephrotoxicity. Pediatr. Nephrol. 2005, 20, 872-885. (Pubitemid 40909254)
17. Vormfelde, S. V.; Schirmer, M.; Hagos, Y.; Toliat, M. R.;Engelhardt, S.; Meineke, I.; Burckhardt, G.; Nurnberg, P.;Brockmoller, J. Torsemide Renal Clearance and Genetic Variationin Luminal and Basolateral Organic Anion Transporters. Br. J. Clin. Pharmacol. 2006, 62, 323-335. (Pubitemid 44215533)
18. Busch, A. E.; Karbach, U.; Miska, D.; Gorboulev, V.; Akhoundova,A.; Volk, C.; Arndt, P.; Ulzheimer, J. C.; Sonders, M. S.;Baumann, C.; Waldegger, S.; Lang, F.; Koepsell, H. Human Neurons Express the Polyspecific Cation Transporter HOCT2, Which Translocates Monoamine Neurotransmitters, Amantadine,and Memantine. Mol. Pharmacol. 1998, 54, 342-352. (Pubitemid 28368824)
19. Kleta, R.; Mohrmann, M.; Schlatter, E. Effects of Cell Differentiationon Ion Conductances and Membrane Voltage in LLC-PK1 Cells. Pfluegers Arch. 1995, 429, 370-377.
20. Pietig, G.; Mehrens, T.; Hirsch, J. R.; Cetinkaya, I.; Piechota, H.; Schlatter, E. Properties and Regulation of Organic Cation Transport in Freshly Isolated Human Proximal Tubules. J. Biol.Chem. 2001, 276, 33741-33746.
21. Wilde, S.; Schlatter, E.; Koepsell, H.; Edemir, B.; Reuter, S.; Pavenstädt, H.; Neugebauer, U.; Schröter, R.; Brast, S.; Ciarimboli, G. Calmodulin-Associated Post-Translational Regulation of Rat Organic Cation Transporter 2 in the Kidney Is Gender Dependent. Cell. Mol. Life Sci. 2009, 66, 1729-1740.
22. Pietruck, F.; Ullrich, K. J. Transport Interactions of Different Organic Cations During Their Excretion by the Intact Rat Kidney. Kidney Int. 1995, 47, 1647-1657.
23. Rohlicek, V.; Ullrich, K. J. Simple Device for Continuous Measurement of Fluorescent Anions and Cations in the Rat Kidney in Situ. Renal Physiol. Biochem. 1994, 17, 57-61. (Pubitemid 24042445)
24. Ciarimboli, G.; Koepsell, H.; Iordanova, M.; Gorboulev, V.; Dürner, B.; Lang, D.; Edemir, B.; Schröter, R.; Van Le, T.; Schlatter, E. Individual PKC-Phosphorylation Sites in Organic Cation Transporter 1 Determine Substrate Selectivity and Transport Regulation. J. Am. Soc. Nephrol. 2005, 16, 1562-1570. (Pubitemid 41716463)
25. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55-63. (Pubitemid 14203433)
26. Busse, D.; Busch, F. W.; Bohnenstengel, F.; Eichelbaum, M.; Fischer, P.; Opalinska, J.; Schumacher, K.; Schweizer, E.; Kroemer, H. K. Dose Escalation of Cyclophosphamide in PatientsWith Breast Cancer: Consequences for Pharmacokinetics andMetabolism. J. Clin. Oncol. 1997, 15, 1885-1896. (Pubitemid 27209518)
27. Chen, T. L.; Kennedy, M. J.; Anderson, L. W.; Kiraly, S. B.;Black, K. C.; Colvin, O. M.; Grochow, L. B. Nonlinear Pharmacokinetics of Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide in Patients With Metastatic Breast Cancer Receiving High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation. Drug Metab. Dispos. 1997, 25,544-551. (Pubitemid 27213094)
28. Schuler, U.; Ehninger, G.; Wagner, T. Repeated High-Dose Cyclophosphamide Administration in Bone Marrow Transplantation: Exposure to Activated Metabolites. Cancer Chemother. Pharmacol. 1987, 20, 248-252. (Pubitemid 17163404)
29. Skinner, R.; Pearson, A. D.; Price, L.; Coulthard, M. G.; Craft, A. W. The Influence of Age on Nephrotoxicity Following Chemotherapy in Children. Br. J. Cancer Suppl. 1992, 18, S30-S35.
30. Allen, L. M.; Creaven, P. J.; Nelson, R. L. Studies on the Human Pharmacokinetics of Isophosphamide (NSC-109724). Cancer Treat. Rep. 1976, 60, 451-458.
31. Creaven, P. J.; Allen, L. M.; Alford, D. A.; Cohen, M. H. Clinical Pharmacology of Isophosphamide. Clin. Pharmacol. Ther. 1974,16, 77-86.
32. Zhang, J.; Tian, Q.; Zhou, S. Clinical Pharmacology of Cyclophosphamide and Ifosfamide. Curr. Drug Ther. 2006, 1, 55-84.
33. Aleksa, K.; Halachmi, N.; Ito, S.; Koren, G. Renal Ontogeny of Ifosfamide Nephrotoxicity. J. Lab. Clin. Med. 2004, 144, 285-293. (Pubitemid 40018015)
34. Springate, J. E. Ifosfamide Metabolite Chloroacetaldehyde Causes Renal Dysfunction in Vivo. J. Appl. Toxicol. 1997, 17, 75-79. (Pubitemid 27091401)
35. Dresser, M. J.; Gray, A. T.; Giacomini, K. M. Kinetic and Selectivity Differences Between Rodent, Rabbit, and Human Organic Cation Transporters (OCT1). J. Pharmacol. Exp. Ther.2000, 292, 1146-1152. (Pubitemid 30136612)
36. Dresser, M. J.; Leabman, M. K.; Giacomini, K. M. Transporters Involved in the Elimination of Drugs in the Kidney: Organic Anion Transporters and Organic Cation Transporters. J. Pharm. Sci. 2001, 90, 397-421. (Pubitemid 32298045)
37. Fujita, T.; Urban, T. J.; Leabman, M. K.; Fujita, K.; Giacomini, K. M. Transport of Drugs in the Kidney by the Human Organic Cation Transporter, OCT2 and Its Genetic Variants. J. Pharm. Sci. 2006, 95, 25-36.
38. Schwerdt, G.; Gordjani, N.; Benesic, A.; Freudinger, R.; Wollny, B.; Kirchhoff, A.; Gekle, M. Chloroacetaldehyde- and Acrolein-Induced Death of Human Proximal Tubule Cells. Pediatr. Nephrol.2006, 21, 60-67. (Pubitemid 43040196)
39. Kleta, R. Fanconi or Not Fanconi? Lowe Syndrome Revisited. Clin. J. Am. Soc. Nephrol. 2008, 3, 1244-1245.
40. Magden, D.; Berger, L.; Coady, M. J.; Ilivitzki, A.; Militianu, D.; Tieder, M.; Selig, S.; Lapointe, J. Y.; Zelikovic, I.; Skorecki, K. A loss-of-function mutation in NaPi-IIa and renal Fanconi'ssyndrome. N. Engl. J. Med. 2010, 362 (12), 1102-1109.
41. Foreman, J. W.; Roth, K. S. Human Renal Fanconi Syndrome - Then and Now. Nephron 1989, 51, 301-306. (Pubitemid 19056718)